Insilico Medicine Analysis: $425M Raised
What is Insilico Medicine?
Insilico Medicine specializes in generative artificial intelligence for drug discovery and development. Their innovative approach significantly reduces the time and cost associated with bringing life-saving medications to market. This transformation enables healthier, longer lives through advanced therapeutic solutions.
Employees
201-500
Founded
2014
Industry
HealthTech, AI/ML, Biotech
Product Features & Capabilities
- PandaOmics for target discovery
- Chemistry42 for chemical synthesis
- Generative Biologics for biologic drug development
- inClinico for clinical trial optimization
- Science42: DORA for data-driven research.
Use Cases
Accelerate drug discovery processes using AI-driven methodologies; Identify new therapeutic targets through advanced data analysis; Optimize clinical trial designs for better outcomes; Develop biologics with enhanced efficacy and safety profiles; Streamline chemical synthesis for faster drug development.
How much Insilico Medicine raised
Series E - $110 million
March 2025Lead Investor: Value Partners Group, Pudong Venture Capital
Series D - $60 million
2022Series C - $255 million
2021Lead Investor: Warburg Pincus and others
Other Considerations
Recognized as one of the most innovative biotechnology companies in 2024; Operates multiple global offices including locations in the US, Canada, and China; Engages in partnerships for sustainability initiatives.
